2021/2022 HCPCS Code Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short Description Brexucabtagene car pos t
HCPCS Coverage Code C = Carrier judgment
HCPCS Action Code N = No maintenance for this code
HCPCS Action Effective Date April 01, 2021
HCPCS Code Added Date April 01, 2021
HCPCS Pricing Indicator Code 51 = Drugs
HCPCS Multiple Pricing Indicator Code A = Not applicable as HCPCS priced under one methodology
HCPCS Type Of Service Code 1 = Medical care
P = Lump sum purchase of DME, prosthetics, orthotics
HCPCS Anesthesia Base Unit Quantity 0